Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
ESMO Open|December 22, 2022
Targeting KRASG12C in colorectal cancer: the beginning of a new eraD Ciardiello, B A Maiorano, E MartinelliAnnals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2020
Clinical development of therapies targeting TGFβ: current knowledge and future perspectivesD Ciardiello, E Elez, J Tabernero, et al.Expert Review of Endocrinology & Metabolism|September 25, 2023
Promising targetable biomarkers in pancreatic neuroendocrine tumoursM Borghesani, L Gervaso, C A Cella, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectivesE Martinelli, D Ciardiello, G Martini, et al.Journal of Neuroendocrinology|June 19, 2025
Clinical/pathological features and survival outcomes of extra-pulmonary neuroendocrine carcinomas: A retrospective single-center seriesL Benini, L Gervaso, S Frassoni, et al.ESMO Gastrointestinal Oncology|February 6, 2026
Role of the microbiome in the development and treatment of gastric cancer: an overview of the biological and clinical landscapeC A Cella, D Ciardiello, L Gervaso, et al.Journal of Experimental & Clinical Cancer Research : CR|December 18, 2019
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpressionS Napolitano, N Matrone, A L Muddassir, et al.ESMO Open|October 23, 2024
Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centersL Algeri, L Falkman, F Spada, et al.Cancer Medicine|March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trialsG Martini, D Ciardiello, V Famiglietti, et al.ESMO Open|August 7, 2024
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective studyL Guidi, C Valenza, E Battaiotto, et al.Pageof 2